Alkermes Reports Q1 Revenue Growth, Narrows Full-Year GAAP Loss & Improves EBITDA Guidance Post-Avadel Acquisition

summarizeSummary

Alkermes reported increased Q1 revenues and narrowed its full-year GAAP net loss and improved EBITDA guidance, reflecting the financial impact and integration of the Avadel acquisition.

check_boxKey Events · Earnings and Guidance · ALKS

• Q1 2026 Financial Results

  Total revenues increased to $392.9 million from $306.5 million year-over-year. The company reported a GAAP net loss of $66.5 million and an EBITDA loss of $30.1 million, but adjusted EBITDA grew to $80.3 million.

• Updated FY2026 Guidance

  Alkermes narrowed its projected GAAP net loss for 2026 to between $70 million and $90 million (from $115 million to $135 million previously) and improved its EBITDA guidance to between $105 million and $135 million (from $60 million to $90 million).

• Avadel Acquisition Impact

  The Q1 results include six weeks of LUMRYZ revenue ($39.5 million) following the Avadel Pharmaceuticals acquisition in February 2026. The improved full-year guidance is attributed to non-cash purchase price accounting adjustments related to this acquisition.

• Share Repurchase Activity

  The company repurchased approximately 1 million ordinary shares for $28 million during Q1 2026, with $172 million remaining under the authorized program.

auto_awesomeAnalysis · ALKS · Life Sciences

Alkermes plc reported strong first-quarter revenue growth, driven by proprietary product sales including the newly acquired LUMRYZ. While the company posted a GAAP net loss and negative EBITDA for Q1 2026, it significantly improved its full-year 2026 GAAP net loss and EBITDA guidance. This positive revision is primarily due to non-cash accounting adjustments related to the Avadel Pharmaceuticals acquisition, which closed in February 2026. The updated outlook suggests a more favorable financial trajectory for the year as the company integrates the acquisition and advances its sleep medicine pipeline.